lifestyle.paraskevas.net

Author: Sanofi Winthrop Industrie

Press Release: Q1 2026: double-digit sales and business EPS growth

April 23, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

April 22, 2026
Press Release: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

April 22, 2026
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

April 22, 2026
Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

April 18, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

April 13, 2026
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

April 7, 2026
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

March 31, 2026
Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

March 30, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

March 27, 2026